{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:20:10Z","timestamp":1771842010788,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Caudal type homeobox 2 (CDX2) is an intestine-specific transcription factor that serves as a diagnostic marker of enteric differentiation and may also reflect tumor behavior and therapeutic susceptibility. Emerging evidence suggests that CDX2 expression may predict sensitivity to fluoropyrimidine-based therapy independent of tissue of origin. We report a retrospective case series of three patients with metastatic adenocarcinoma (aggressive variant prostate, minor salivary gland, and intestinal-type sinonasal tract) exhibiting strong CDX2 nuclear expression. In all cases, tumors were refractory to or lacked established standard systemic therapy. Treatment decisions were informed by the CDX2-positive enteric phenotype, leading to the initiation of fluoropyrimidine-based regimens. Response was assessed using PET-CT and MRI. All three patients achieved marked metabolic and clinical responses, including a sustained complete metabolic response in the prostate cancer case and durable disease control in the salivary gland and sinonasal tumors. These findings highlight CDX2 as a potential biomarker requiring validation, which may identify tumors intrinsically susceptible to fluoropyrimidines regardless of anatomical origin. CDX2 immunohistochemistry is widely available and inexpensive, and may complement genomic profiling in rare malignancies or in settings where standard treatment algorithms are limited. This report is hypothesis-generating and not intended to estimate response rates or treatment efficacy.<\/jats:p>","DOI":"10.3390\/curroncol33020126","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:58:21Z","timestamp":1771837101000},"page":"126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDX2 Expression and Fluoropyrimidine Response in Rare Non-GI Tumors: A Three-Case Series"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-5022","authenticated-orcid":false,"given":"Riham","family":"Suleiman","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Dipp","family":"Garcia","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Aut\u00f3noma de Guadalajara, Av. Patria 1201, Lomas del Valle, Zapopan C.P. 45129, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binav","family":"Baral","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-1257","authenticated-orcid":false,"given":"Thorvardur","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Fuentes-Bayne","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1469-1809.1997.6150393.x","article-title":"Cloning and chromosome assignment of the human CDX2 gene","volume":"61","author":"Drummond","year":"1997","journal-title":"Ann. Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2000.18142","article-title":"Cdx1 and cdx2 expression during intestinal development","volume":"119","author":"Silberg","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/MCB.16.2.619","article-title":"An intestine-specific homeobox gene regulates proliferation and differentiation","volume":"16","author":"Suh","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31909","DOI":"10.1074\/jbc.M204622200","article-title":"Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription: Implication for the developmental regulation of the sucrase-isomaltase gene","volume":"277","author":"Boudreau","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1042\/bj3220833","article-title":"Regulation of lactase-phlorizin hydrolase gene expression by the caudal-related homoeodomain protein Cdx-2","volume":"322","author":"Troelsen","year":"1997","journal-title":"Biochem. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0016-5085(00)70420-3","article-title":"The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation","volume":"118","author":"Fang","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15229","DOI":"10.1016\/S0021-9258(17)36596-1","article-title":"Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium","volume":"269","author":"James","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/01.MP.0000086073.92773.55","article-title":"Cdx2 Protein Expression in Normal and Malignant Human Tissues: An Immunohistochemical Survey Using Tissue Microarrays","volume":"16","author":"Moskaluk","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0006-291X(02)00480-1","article-title":"Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice","volume":"294","author":"Mutoh","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/gast.2002.31902","article-title":"Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice","volume":"122","author":"Silberg","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"doaf061-237","DOI":"10.1093\/dote\/doaf061.237","article-title":"423. Gastric metaplasia of oesophageal mucosa in a patient with gerd: CDX2 expression as a possible prognostic criterion for barrett\u2019s oesophagus","volume":"38","author":"Livzan","year":"2025","journal-title":"Dis. Esophagus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAI.0000000000001216","article-title":"Use of SATB2 and CDX2 Immunohistochemistry to Characterize and Diagnose Colorectal Cancer","volume":"32","author":"Kato","year":"2024","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.5858\/2005-129-1100-CIAUMO","article-title":"CDX2 is a useful marker of intestinal-type differentiation: A tissue microarray-based study of 629 tumors from various sites","volume":"129","author":"Morrison","year":"2005","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000478-200303000-00003","article-title":"CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas","volume":"27","author":"Werling","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/PL00011741","article-title":"Expression of Cdx1 and Cdx2 mRNAs and relevance of this expression to differentiation in human gastrointestinal mucosa\u2014With special emphasis on participation in intestinal metaplasia of the human stomach","volume":"4","author":"Mizoshita","year":"2001","journal-title":"Gastric. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.21276\/SSR-IIJLS.2025.11.1.34","article-title":"Utility of CDX2 Expression in Adenocarcinoma with Special Reference to the Gastrointestinal Tract","volume":"11","author":"Gupta","year":"2025","journal-title":"SSR Inst. Int. J. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xiao, W., Hong, H., Awadallah, A., Zhou, L., and Xin, W. (2014). Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086853"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/01.pas.0000126856.09058.71","article-title":"Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas: An immunohistochemical study of 22 cases utilizing CDX2 and MUC2","volume":"28","author":"Cathro","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00000478-200404000-00003","article-title":"Primary mucinous (so-called colloid) carcinomas of the lung: A clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression","volume":"28","author":"Rossi","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Li, J., Sandhu, A., Smith, M., Larsen, B.T., Tazelaar, H.D., Bernadt, C.T., Ritter, J.H., Lin, C.-Y., and Wein, A.N. (2025). The Utility of CDX2 and CK20 Immunohistochemical Reactivity to Distinguish Adenocarcinomas of the Lung From Their Benign Mimics. Arch. Pathol. Lab. Med., 1.","DOI":"10.5858\/arpa.2025-0271-OA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21873\/cgp.20151","article-title":"Regulation of REG4 Expression and Prediction of 5-Fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma","volume":"16","author":"Koh","year":"2019","journal-title":"Cancer Genom Proteom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.32074\/1591-951X-19-19","article-title":"Expression of CDX2 in metastatic prostate cancer","volume":"111","author":"Guerrieri","year":"2019","journal-title":"Pathologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0210-4806(04)73048-X","article-title":"Expression of CDX2 in urinary bladder and urethra lesions","volume":"28","year":"2004","journal-title":"Actas Urol. Esp."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Aasebo, K., Dragomir, A., Sundstr\u00f6m, M., Mezheyeuski, A., Edqvist, P.H., Eide, G.E., Ponten, F., Pfeiffer, P., Glimelius, B., and Sorbye, H. (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better Mutated and a Worse Mutated Subgroup. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00008"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12015-025-10978-6","article-title":"CDX2 Promotes Hepatic Specification of hiPSC-derived Endoderm Through the PI3K\u2013Akt\u2013GSK3\u03b2 Pathway for Improved Therapeutic Efficacy","volume":"22","author":"Bai","year":"2026","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105515","DOI":"10.1016\/j.esmoop.2025.105515","article-title":"CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary","volume":"10","author":"Suleiman","year":"2025","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A","article-title":"Adriamycin\/cis-platinum\/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland","volume":"47","author":"Alberts","year":"1981","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","article-title":"Sinonasal carcinoma: Clinical, pathological, genetic and therapeutic advances","volume":"11","author":"Llorente","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/s41388-025-03365-5","article-title":"CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer","volume":"44","author":"Wouters","year":"2025","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1038\/s41598-025-07278-x","article-title":"CDX2 loss in colorectal cancer cells is associated with invasive properties and tumor budding","volume":"15","author":"Bodmer","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1506597","article-title":"CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer","volume":"374","author":"Dalerba","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41419-018-1263-9","article-title":"CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt\/\u03b2-catenin signaling via transactivation of GSK-3\u03b2 and Axin2 expression","volume":"10","author":"Yu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/mp.55.5.310","article-title":"Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines","volume":"55","author":"Derenzini","year":"2002","journal-title":"Mol. Pathol."},{"key":"ref_39","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_40","first-page":"6184","article-title":"CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer","volume":"14","author":"Saito","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1158\/1078-0432.CCR-09-0401","article-title":"Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer","volume":"15","author":"Baba","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:33:04Z","timestamp":1771839184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020126"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020126","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]}}}